Frontlight ResearchEarly access
CompletedPhase 2
Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery
Key facts
- Who runs it
- VivaVision Biotech, Inc
- Where
- Austin, Cincinnati, Grand Junction, Houston, Inglewood, Jacksonville, Las Vegas, Petaluma, Rancho Cordova, and Washington, United StatesSee the 10 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 91 people enrolled
- Started
- 11 Jan 2024
- Ended
- 15 May 2024
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- VVN461 Ophthalmic Solution 1.0%
- VVN461 Ophthalmic Solution 0.5%
- Vehicle
- Record updated
- 11 September 2026
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- ≥21 years of age and in good general health at Visit 1 (Screening)
- Willing and able to provide informed consent and provide relevant privacy authorization(s)
- Willing and able to comply with study requirements and visit schedule
- Clear ocular media (other than cataract) in the study eye
- Planning to undergo routine unilateral cataract surgery via phacoemulsification extraction and implantation of an intraocular lens
Who cannot take part
- Recent use of corticosteroids or oral non-steroidal anti-inflammatory drugs
- Any ocular pain at Visit 1 (Screening)
Where in United States
- Keystone ResearchAustin, United States
- Cincinnati Eye InstituteCincinnati, United States
- ICON Eye CareGrand Junction, United States
- Houston Eye AssociatesHouston, United States
- United medical research instituteInglewood, United States
- Levenson Eye AssociatesJacksonville, United States
- Center for Sight Las VegasLas Vegas, United States
- North Bay Eye AssociatesPetaluma, United States
- Martel Eye AssociatesRancho Cordova, United States
- Comprehensive Eye Care, Ltd.Washington, United States
About the trial
What the trial wants to find out
This is a multicenter, double-masked, randomized, vehicle-controlled, parallel-comparison study conducted at sites in the United States (US) in subjects undergoing routine unilateral cataract extraction and lens replacement (CELR) surgery via phacoemulsification
The 3 groups in the trial
- VVN461 1.0%Treatment being tested
VVN461 Ophthalmic Solution, 1.0%
Treatment: VVN461 Ophthalmic Solution 1.0%
- VVN461 0.5%Treatment being tested
VVN461 Ophthalmic Solution, 0.5%
Treatment: VVN461 Ophthalmic Solution 0.5%
- VehiclePlacebo, for comparison
VVN461 Vehicle
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2, Double-masked, Randomized, Vehicle-controlled Study of VVN461 Ophthalmic Solution in Treating Post -Operative Ocular Inflammation in Subjects Undergoing Routine Unilateral Cataract Surgery
- Record updated
- 11 September 2026